en
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Open in Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Show more

๐Ÿ“ˆ Analytical overview of Telegram channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) in the Arabic language segment is an active participant. Currently, the community unites 13 355 subscribers, ranking 1 923 in the Medicine category and 5 681 in the Saudi Arabia region.

๐Ÿ“Š Audience metrics and dynamics

Since its creation on ะฝะตะฒั–ะดะพะผะพ, the project has demonstrated rapid growth, gathering an audience of 13 355 subscribers.

According to the latest data from 27 June, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 213 over the last 30 days and by -17 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 27.63%. Within the first 24 hours after publication, content typically collects 9.86% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 3 695 views. Within the first day, a publication typically gains 1 318 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 36.
  • Thematic interests: Content is focused on key topics such as ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ.

๐Ÿ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Thanks to the high frequency of updates (latest data received on 28 June, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

13 355
Subscribers
-1724 hours
+3037 days
+21330 days
Posts Archive
ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุทู„ุงุจ ู‚ุจู„ ู„ุง ุชู†ุฒู„ ุงู„ู…ุญุงุถุฑุฉ ุงู„ุซุงู†ูŠุฉ ุงู† ุดุงุก ุงู„ู„ู‡ ุงู„ูŠูˆู… ุญูุธูˆู„ูŠ ุงู„ุงุฏูˆูŠุฉ ุจู‡ุงูŠ ุงู„ุทุฑูŠู‚ุฉ ุงู„ุฌูŠู„ ุงู„ุงูˆู„ ุงุบู„ุจู‡ ูŠู†ุชู‡ูŠ ุจ ุงู„ู…ู‚ุทุน
ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุทู„ุงุจ ู‚ุจู„ ู„ุง ุชู†ุฒู„ ุงู„ู…ุญุงุถุฑุฉ ุงู„ุซุงู†ูŠุฉ ุงู† ุดุงุก ุงู„ู„ู‡ ุงู„ูŠูˆู… ุญูุธูˆู„ูŠ ุงู„ุงุฏูˆูŠุฉ ุจู‡ุงูŠ ุงู„ุทุฑูŠู‚ุฉ
ุงู„ุฌูŠู„ ุงู„ุงูˆู„ ุงุบู„ุจู‡ ูŠู†ุชู‡ูŠ ุจ ุงู„ู…ู‚ุทุน Azine ุนุฏุง haloperidol ูˆ Loxapine ุงู„ุฌูŠู„ ุงู„ุซุงู†ูŠ ุงุบู„ุจู‡ู† ูŠู†ุชู‡ู† ุจุงู„ู…ู‚ุทุน done ูˆ apine ูˆ azole ู…ุง ุนุฏุง Cariprazine ูˆ Lumateperone
#schizophrenia

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… (ู…ูู†ูŽ ุงู„ู…ูุคู’ู…ูู†ููŠู†ูŽ ุฑูุฌูŽุงู„ูŒ ุตูŽุฏูŽู‚ููˆุง ู…ูŽุง ุนูŽุงู‡ูŽุฏููˆุง ุงู„ู„ู‡ูŽ ุนูŽู„ูŽูŠู’ู‡ู ููŽู…ูู†ู’ู‡ูู…ู’ ู…ูŽู†ู’ ู‚ูŽุถูŽู‰ ู†ูŽุญู’ุจูŽู‡ู ูˆูŽู…ูู†ู’ู‡ูู…ู’ ู…ูŽู†ู’ ูŠูŽู†ู’ุชูŽุธูุฑู ูˆูŽู…ูŽุง ุจูŽุฏูŽู‘ู„ููˆุง ุชูŽุจู’ุฏููŠู„ู‹ุง) ุตุฏู‚ ุงู„ู„ู‡ ุงู„ุนู„ูŠ ุงู„ุนุธูŠู… ุฅู†ุง ู„ู„ู‡ ูˆุฅู†ุง ุฅู„ูŠู‡ ุฑุงุฌุนูˆู†

ุงู„ู„ู‡ู… ุญูŽุตู‘ูู†ู’ ุซูุบููˆุฑูŽ ุงู„ู’ู…ูุณู’ู„ูู…ููŠู†ูŽ ุจูุนูุฒู‘ูŽุชููƒูŽ ุงู„ู„ู‘ูŽู‡ูู…ู‘ูŽ ุงุบู’ุฒู ุจููƒูู„ู‘ู ู†ูŽุงุญููŠูŽุฉู ู…ูู†ูŽ ุงู„ู’ู…ูุณู’ู„ูู…ููŠู†ูŽ ุนูŽู„ูŽู‰ ู…ูŽู†ู’ ุจูุฅูุฒูŽุงุฆูู‡ูู…ู’ ู…ูู†ูŽ ุงู„ู’ู…ูุดู’ุฑููƒููŠู†ูŽ ุŒ ูˆูŽ ุฃูŽู…ู’ุฏูุฏู’ู‡ูู…ู’ ุจูู…ูŽู„ูŽุงุฆููƒูŽุฉู ู…ูู†ู’ ุนูู†ู’ุฏููƒูŽ ู…ูุฑู’ุฏููููŠู†ูŽ ุŒ ุญูŽุชู‘ูŽู‰ ูŠูŽูƒู’ุดููููˆู‡ูู…ู’ ุฅูู„ูŽู‰ ู…ูู†ู’ู‚ูŽุทูŽุนู ุงู„ุชู‘ูุฑูŽุงุจู ู‚ูŽุชู’ู„ู‹ุง ูููŠ ุฃูŽุฑู’ุถููƒูŽ ูˆูŽ ุฃูŽุณู’ุฑุงู‹ ุŒ ุฃูŽูˆู’ ูŠูู‚ูุฑู‘ููˆุง ุจูุฃูŽู†ู‘ูŽูƒูŽ ุฃูŽู†ู’ุชูŽ ุงู„ู„ู‘ูŽู‡ู ุงู„ู‘ูŽุฐููŠ ู„ูŽุง ุฅูู„ูŽู‡ูŽ ุฅูู„ู‘ูŽุง ุฃูŽู†ู’ุชูŽ ูˆูŽุญู’ุฏูŽูƒูŽ ู„ูŽุง ุดูŽุฑููŠูƒูŽ ู„ูŽูƒูŽ

ูˆุฒุงุฑูŠ 2025 ุฏูˆุฑ 1
T.l 65 years old man who recently diagnosed to have advanced prostate cancer. He has a history of uncontrolled diabetes mellitus and hypertension. What is the best hormonal therapy for this patient? A) Flutamide B) Relugolix C) Leuprolide D) Degarelix E) Nilutamide
ุฎู„ูŠ ู†ุชูู‚ ุนู„ู‰ ูƒู… ู†ู‚ุทุฉ: ุงู„ุญุงู„ุฉ advance prostate cancer ูŠุนู†ูŠ ุงู„ูƒุงู†ุณุฑ ู…ู†ุชุดุฑ ูˆูˆุงุตู„ ุงู„ู‰ ู…ุฑุญู„ุฉ ู…ุชู‚ุฏู…ุฉ / ูŠุนู†ูŠ ู‡ู†ุง ู„ุงุฒู… ู†ุฎุชุงุฑ ุนู„ุงุฌ ูŠู‚ู„ู„ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุงู„ู‰ castrate level ูู…ู† ู‡ุณู‡ ุงุณุชุจุนุฏู†ุง A , E ู„ุงู† ู…ุงูƒูˆ ูุงูŠุฏุฉ ู…ู† ู‚ูู„ ุงู„ุฑุณุจุชุฑุงุช ูู‚ุท ูˆุฐูƒุฑุช ุจุงู„ู…ุญุงุถุฑุฉ ุงู†ู‡ ุงุณุชุฎุฏุงู…ู‡ู… ฺฉ monotherapy ู…ุง ุฑุญ ูŠููŠุฏู†ู‡ ุงู„ู…ุฑูŠุถ ูŠุนุงู†ูŠ ู…ู† ุถุบุท ูˆุณูƒุฑูŠ ุดูˆููˆุง ุดุจุงุจ ุงู„ุชูŠุณุชูˆุณุชูŠุฑูˆู† ู…ู† ูŠู‚ู„ ุงู„ู‰ ู…ุณุชูˆูŠุงุช ู…ู†ุฎูุถุฉ ุฑุญ ุชุตูŠุฑ ุฒูŠุงุฏุฉ ุจ ู…ู‚ุงูˆู…ุฉ ุงู„ุงู†ุณูˆู„ูŠู† ูˆูƒู„ ุงู„ุนู„ุงุฌุงุช ุงู„ู…ุฐูƒูˆุฑุฉ ุณูˆุงุก LHRH agonist GnRH antagonists ุชุณุจุจ ู†ู‚ุตุงู† ูƒุจูŠุฑ ุจู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ูˆุชุตูŠุฑ ุฒูŠุงุฏุฉ ุจู…ู‚ุงูˆู…ุฉ ุงู„ุงู†ุณูˆู„ูŠู† ูˆูŠุฑุชูุน ู…ุณุชูˆู‰ ุงู„ุณูƒุฑ ููŠ ุงู„ุฏู… ุฒูŠู† ุดู†ูˆ ุชุฃุซูŠุฑ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุนู„ู‰ ุงู„ู‚ู„ุจ ูˆุงู„ุงูˆุนูŠุฉ ุงู„ุฏู…ูˆูŠุฉุŸ ู†ู‚ุตุงู† ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุฑุญ ูŠุตูŠุฑ ุงุฑุชูุงุน ุจุงู„ุฏู‡ูˆู† ุงู„ุซู„ุงุซูŠุฉ TG ุงุฑุชูุงุน ุงู„ูƒูˆู„ูŠุณุชูŠุฑูˆู„ LDL ูˆุงุญุชู…ุงู„ ุงุฑุชูุงุน ุถุบุท ุงู„ุฏู… ุฒูŠู† ู‡ู†ุง ุงู„ู…ุฑูŠุถ ุนู†ุฏู‡ ุถุบุท ูˆุณูƒุฑ ุดู†ุฎุชุงุฑุŸ ู…ู†ูˆ ุงู„ู…ุฌู…ูˆุนุฉ ุงู„ูŠ ุชุณูˆูŠ flare up ุŸ LHRH agonists ูŠุนู†ูŠ ุจุงู„ุจุฏุงูŠุฉ ุชุณูˆูŠ ุฒูŠุงุฏุฉ ู…ูุงุฌุฆุฉ ุจ ุงูุฑุงุฒ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู†ุŒ ูˆูŠู† ุงู„ู…ุดูƒู„ุฉุŸ ุงู„ุงุฑุชูุงุน ุงู„ู…ูุงุฌุฆ ุจ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุฑุญ ูŠุณุจุจ ุฒูŠุงุฏุฉ ุงู„ู€ risk of MI or stroke ูˆู‡ูˆ ุงุตู„ุง ุนู†ุฏู‡ risk factor ุนู†ุฏู‡ Hypertension ูˆ DM ุงุฐู† ู†ุณุชุจุนุฏ LHRH agonist ุงู„ูŠ ู‡ูˆ C ู„ุงู† ุฑุญ ูŠุฒุฏุงุฏ ุงู„ risk of CVD ุจู‚ูŠู†ู‡ ุจูŠู† ุงุฎุชูŠุงุฑูŠู† ูˆุงุซู†ูŠู†ู‡ู… ู…ู† ู†ูุณ ุงู„ุนุงุฆู„ุฉ GnRH antagonists ู„ูƒู† ูˆุงุญุฏ ุงู†ุทูŠู‡ ู…ุฑุฉ ูˆุงุญุฏุฉ ุดู‡ุฑูŠุง ูˆุงู„ุซุงู†ูŠ ู…ุฑุฉ ูŠูˆู…ูŠุง ู…ุง ุฏุงู… ุงู„ู…ุฑูŠุถ ูˆุงุตู„ ุงู„ู‰ ู…ุฑุงุญู„ ู…ุชู‚ุฏู…ุฉ ูˆูŠุนุงู†ูŠ ู…ู† ุงู…ุฑุงุถ ุซุงู†ูˆูŠุฉ ุงู„ุงูุถู„ ุงู†ู‡ ู†ุฎุชุงุฑ ุฏูˆุงุก ุณู‡ู„ ุงู„ุงู„ุชุฒุงู… ู…ู† ู‚ุจู„ ุงู„ู…ุฑูŠุถ ู„ุงู† ุงูŠ ู†ุณูŠุงู† ู„ู„ุฌุฑุนุฉ ุฑุญ ูŠุณุจุจ ุงุฑุชูุงุน ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ูˆุฒูŠุงุฏุฉ ุงุนุฑุงุถ ุงู„ prostate cancer
ุงู„ุฌูˆุงุจ D ู„ุนุฏุฉ ุงุณุจุงุจ: ูŠู†ุฒู„ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุฅู„ู‰ ุงู‚ู„ ู…ุณุชูˆู‰ ู…ุง ูŠุณุจุจ flare up ุณู‡ู„ ุงู„ุงู„ุชุฒุงู… ู…ุฑุฉ ูˆุงุญุฏุฉ ุดู‡ุฑูŠุง ู…ู† ุฎู„ุงู„ ุงู„ุญู‚ู† ุชุญุช ุงู„ุฌู„ุฏ
#Prostate_Cancer ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Mr. Ali, 66, has metastatic prostate cancer with bone metastases. He's experiencing significant pain. Which treatment is most likely to provide pain relief from his bone metastases? A) Leuprolide B) Bicalutamide C) External beam radiation therapy D) Abiraterone E) Enzalutamice 2025 ุฏูˆุฑ 1 ุทุจุนุง ุงู„ุณุคุงู„ ูŠุญุชุงุฌ ุชุฑูƒูŠุฒ ู‡ูŠ ุงู„ุนู„ุงุฌุงุช ุงู„ู…ุฐูƒูˆุฑุฉ ุชุนุงู„ุฌ ุงู„ูƒุงู†ุณุฑ ุงูˆูƒ ุจุณ ู…ุง ุฑุญ ุชุฎูู ุงู„ู… ุงู„ุนุธุงู… ูู‡ูˆ ูƒุงุชุจ ูŠุฑูŠุฏ ุนู„ุงุฌ ูŠุฎูู ุงู„ุงู„ู… ู…ุจุงุดุฑุฉ ู‡ู†ุง External beam radiation therapy ุญุชู‰ ู†ุฏู…ุฑ ุงู„ุฎู„ุงูŠุง ุงู„ุณุฑุทุงู†ูŠุฉ ุงู„ู…ูˆุฌูˆุฏุฉ ุจุงู„ุนุธุงู… ูˆุจุดูƒู„ ุณุฑูŠุน ุงู„ุนู„ุงุฌุงุช ุงู„ุจู‚ูŠุฉ ุชุณุชุฎุฏู… ู„ู‡ุงูŠ ุงู„ุญุงู„ุฉ ุชุญุณู† ุงู„ุจู‚ุงุก ุชู‚ู„ู„ ุชู‚ุฏู… ุงู„ู…ุฑุถ ุจุณ ู…ุง ุฑุญ ุชุฎูู ุงู„ุงู„ู… ุจุดูƒู„ ุณุฑูŠุน

C.R A 69-year-old man with nonmetastatic castration-resistant prostate cancer (CRPC) wishes to delay the initiation of chemotherapy. Which of the following medications would be most appropriate?
Anonymous voting

A 54 years old male diagnosed with prostate cancer and was preseribed relugolix, the major advantage of GnRH antagonists over LHRH agonists is:
Anonymous voting

ุดู†ูˆ ุงู„ูุฑู‚ ุจูŠู† ู‡ุฐู‡ ุงู„ู…ุตุทู„ุญุงุช: ๐Ÿ”น Metastatic Castration Resistant Prostate Cancer ๐Ÿ”น non Metastatic Castration Resistant Prostate Cancer ๐Ÿ”น Metastatic Castration Naรฏve Prostate Cancer
๐Ÿซ† Metastatic CRPC ุงูˆู„ ุญุงู„ุฉ ุงู„ูƒุงู†ุณุฑ ู…ู†ุชุดุฑ ูˆู…ู‚ุงูˆู… ู„ู„ู€ Castration ู…ู‚ุงูˆู… ู„ู…ุณุชูˆู‰ ุงู„ุงุฎุตุงุก (ุงู‚ู„ ู…ุณุชูˆู‰ ู…ู† Testosterone) ูŠุนู†ูŠ ุจุงู„ุฑุบู… ู…ู† ุชู‚ู„ูŠู„ ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุงู„ุง ุงู†ู‡ ุงู„ู…ุฑุถ ุฌุงูŠ ูŠุชู‚ุฏู… ูˆู„ุง ูƒุฃู†ูˆ ู…ู‚ู„ู„ูŠู† ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† (ุชุนู„ู… ุจุนูŠุด ุจุฏูˆู† ุงู„ุชุณุชูˆุณุชูŠุฑูˆู†) ๐Ÿซ† Non Metastatic CRPC ู†ูุณ ุงู„ููƒุฑุฉ ู„ูƒู† ุงู„ูƒุงู†ุณุฑ ุจุนุฏู‡ ู…ุง ู…ู†ุชุดุฑ ุจุงู‚ูŠ ูู‚ุท ุจุงู„ุจุฑูˆุณุชุงุช, ุจุณ ู‡ู…ูŠู†ู‡ ุฌุงูŠ ูŠุชู‚ุฏู… ุฑุบู… ุชู‚ู„ูŠู„ ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† (ุชุนู„ู… ูŠุนูŠุด ุจุฏูˆู† ุงู„ุชุณุชูˆุณุชูŠุฑูˆู†) ๐Ÿซ† Metastatic C Naรฏve PC ู‡ู†ุง ุงู„ูƒุงู†ุณุฑ ู…ู†ุชุดุฑ ูˆู…ุณูˆูŠู† Castration ู„ูƒู† ุงู„ูƒุงู†ุณุฑ ุญุชู‰ ู„ูˆ ูƒู…ูŠุฉ ู‚ู„ูŠู„ุฉ ุจุงู‚ูŠุฉ ู…ู† ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ูŠุณุญุจู‡ุง ูˆูŠุณุชูุงุฏ ู…ู†ู‡ุง ุงูˆ ูŠุจุฏูŠ ูŠุณุญุจ ู…ู† ุบูŠุฑ ู…ุตุงุฏุฑ ู…ุซู„ุง ู…ู† ุงู„ู€ adrenal gland (ุจุนุฏู‡ ูŠุฏูˆุฑ ุนู„ู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุญุชู‰ ู„ูˆ ู‚ุทุฑุฉ ู‚ุทุฑุฉ ูˆู…ู†ูŠู† ู…ุง ูƒุงู†) ุงูˆ ุงุตู„ุง ุจุนุฏู†ู‡ ู…ุง ู…ุณูˆูŠู† Castration
ุดู†ูˆ Castration๐Ÿค”ุŸ ุชู‚ู„ูŠู„ ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุงู„ู‰ ุงู‚ู„ ู…ุณุชูˆู‰(ู…ุณุชูˆู‰ ุงู„ุงุฎุตุงุก) ู…ู† ุฎู„ุงู„ : Surgery (Orchiectomy) Drugs(LHRH agonist) Drugs summary:
๐Ÿ”ธEnzalutamideโž” non-metastatic CRPC metastatic C naรฏve PC metastatic CRPC to delay the initiation of chemotherapy ๐Ÿ”ธDarolutamideโž” nonmetastatic CRPC ๐Ÿ”ธAbirateroneโž” metastatic C naรฏve PC metastatic CRPC ๐Ÿ”ธDocetaxel, combined with prednisoneโž” improves survival in CRPC ๐Ÿ”ธSipuleucel Tโž” asymptomatic or minimally symptomatic metastatic CRPC ๐Ÿ”ธOlaparib and rucaparibโž” metastatic CRPC ๐Ÿ”ธRadium223โž” metastatic CRPC with symptomatic primary bone metastases
#Prostate_Cancer ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุทู„ุงุจ ู‡ูˆ ุงุฐุง Hormone receptor Positive ุงูƒูŠุฏ ู†ุณุชุฎุฏู… endocrine therapy ู ุดู†ูˆ ู‡ุงู„ุชู†ุงู‚ุถ ุจู‡ุงูŠ ุงู„ุตูˆุฑุฉ ู‡ู†ุง ุงูƒูˆ ุฎุทุฃ ุจุงู„ู…ู†ู‡ุฌ ุงู„ู…ูˆุญุฏ ูˆุฑุฌ
+1
ุทู„ุงุจ ู‡ูˆ ุงุฐุง Hormone receptor Positive ุงูƒูŠุฏ ู†ุณุชุฎุฏู… endocrine therapy ู ุดู†ูˆ ู‡ุงู„ุชู†ุงู‚ุถ ุจู‡ุงูŠ ุงู„ุตูˆุฑุฉ ู‡ู†ุง ุงูƒูˆ ุฎุทุฃ ุจุงู„ู…ู†ู‡ุฌ ุงู„ู…ูˆุญุฏ ูˆุฑุฌุนุช ุชุฃูƒุฏุช ู…ู† ุงู„ู…ุตุฏุฑ ูƒุงุชุจ negative ูˆู‡ุฐุง ุงู„ุตุญ ููŠ ุญุงู„ุฉ Hormone receptor Negative ู‡ู†ุง ู…ุง ู†ู†ุทูŠ endocrine therapy ูˆู†ุจุฏูŠ ุจุงู„ุนู„ุงุฌ ุงู„ูƒูŠู…ูŠุงูˆูŠ ูŠุนู†ูŠ ู…ุฎุชุตุฑ ุงู„ุนุจุงุฑุฉ ุจุดูƒู„ ูƒุงู…ู„
ููŠ ุญุงู„ุฉ Hormone receptorโ€“negative tumors (ER-/PR-) ู‡ุฐูˆู„ ุงู„ู…ุฑุถู‰ ู…ุง ูŠุณุชููŠุฏูˆู† ู…ู† ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ ุฃุตู„ุงู‹ุŒ ู„ุฐู„ูƒ ุงู„ุนู„ุงุฌ ุงู„ูƒูŠู…ูŠุงุฆูŠ ูŠูƒูˆู† ุฎูŠุงุฑ ุฃุณุงุณูŠ ู…ู† ุงู„ุจุฏุงูŠุฉ
ุจุญุงู„ุฉ Triple Negative Breast Cancer ูŠุนู†ูŠ: -ER- , PR- ,HER2 ู…ุงูƒูˆ ูˆู„ุง ู‡ุฏู ู…ูˆุฌูˆุฏ ู„ุง ุฌูŠู†ูŠ ูˆู„ุง ู‡ุฑู…ูˆู†ูŠ ุŒ ู„ุฐู„ูƒ ุงู„ุนู„ุงุฌ ุงู„ุฑุฆูŠุณูŠ ูŠูƒูˆู† ุงู„ูƒูŠู…ูŠุงูˆูŠ
ุงู…ุง ุจุงู„ุงุฎูŠุฑ ู‡ู†ุง ุฑูƒุฒูˆุง ุงุฐุง ุงู„ุญุงู„ุฉ Hormone receptorโ€“positive tumors ู‡ู†ุง ู†ุจุฏูŠ ุจู€ ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ ยฑ ุนู„ุงุฌ ู…ูˆุฌู‡ ุŒ ู„ูƒู† ู†ู„ุฌุฃ ู„ู„ูƒูŠู…ูŠุงูˆูŠ ุฅุฐุง ูุดู„ ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ
#Breast_Cancer ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุตุจุญูƒู… ุงู„ู„ู‡ ุจุงู„ุฎูŠุฑโ™ฅ๏ธ ุดุจุงุจ ู‚ุฑุฑุช ุงู†ู‡ ุงู†ุชู‚ู„ ุจุงู„ุดุฑุญ ู„ู…ูˆุงุถูŠุน ุงู„ู†ูุณูŠุฉ ู‚ุจู„ ู„ุง ุงูƒู…ู„ ุขุฎุฑ ู…ุญุงุถุฑุฉ ู…ู† ุงู„ูƒุงู†ุณุฑ ุงู„ูŠ ู‡ูŠ Adverse effect ุจุญูŠุซ ุฑุญ ุชู†ุฒู„ ู…ุญุงุถุฑุงุช ุงู„ู†ูุณูŠุฉ ุทุจูŠุนูŠ ู„ูƒู† ู…ุง ุจูŠู† ุงู„ู…ุญุงุถุฑุงุช ุฑุญ ุชู†ุฒู„ ู…ู‚ุงุทุน ู‚ุตูŠุฑุฉ ู„ู…ุญุงุถุฑุฉ ุงู„ูƒุงู†ุณุฑ ุงู„ุงุฎูŠุฑุฉ ูŠุนู†ูŠ ู…ุญุงุถุฑุฉ ุงู„ูƒุงู†ุณุฑ ุงู„ุงุฎูŠุฑุฉ ุฑุญ ุชู†ุฒู„ ุนู„ู‰ ุงู‚ุณุงู… ู…ู…ูƒู† 5 ุงูˆ 6 ุงูˆ ุงู‚ู„ ุจุดูƒู„ ููŠุฏูŠูˆู‡ุงุช ู‚ุตูŠุฑุฉ ู…ู…ูƒู† 15 ุงูˆ 20 ุฏู‚ูŠู‚ุฉ ุญุชู‰ ู‡ู… ุงูƒู…ู„ู‡ุง ุงู„ูƒู… ูˆุงู†ุง ุงุฏุฑูŠ ุงูƒูˆ ุจูŠูƒู… ู…ุง ูŠุฑูŠุฏ ุจุณ ูŠู‚ุฑุง ุงู„ู…ุญุงุถุฑุฉ ูˆู‡ุงูŠ ู‡ูŠ ูˆุงู†ู…ุง ูŠุฑูŠุฏ ูŠูู‡ู…ู‡ุง ุจุงู„ุชูุตูŠู„ ุงู„ู…ู…ู„ ูƒู„ ุณุทุฑ ูˆูƒู„ ูƒู„ู…ุฉ ู ุญุชู‰ ู…ุง ูŠุตูŠุฑ ุชุฃุฎูŠุฑ ุงูƒุซุฑ ู…ู† ุงู„ู„ุงุฒู… ูˆู„ู…ุตู„ุญุฉ ุงู„ุฌู…ูŠุน (ุฅู† ูƒุงู†ุช ุงู„ุนู„ุงุฌูŠุงุช ูˆุฒุงุฑูŠ)ุŒ ุงู† ุดุงุก ุงู„ู„ู‡ ู†ุจุฏูŠ ุจุงู„ู†ูุณูŠุฉ ู…ู† ุงู„ูŠูˆู…. ู…ูˆูู‚ูŠู† ุฌู…ูŠุนุง ๐Ÿ™ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุดุจุงุจ ุงู„ูŠูˆู… ูŠู†ุฒู„ ุงุฎุฑ ุจุงุฑุช prostate cancer ุจุณ ุงุฑุฌุน ู„ู„ุจูŠุช ุงูƒู…ู„ู‡ ูˆุงู†ุฒู„ู‡ ุงู† ุดุงุก ุงู„ู„ู‡

ุทู„ุงุจ ุงู„ุฑุงุจุนุฉโ™ฅ๏ธ ุฑุงุฌุนูˆุง ุงู„ุนุจุงุฑุฉ ูˆุงู‚ุฑูˆุง ุงู„ุชูˆุถูŠุญ ู„ู…ู† ุณุฃู„
ุทู„ุงุจ ุงู„ุฑุงุจุนุฉโ™ฅ๏ธ ุฑุงุฌุนูˆุง ุงู„ุนุจุงุฑุฉ ูˆุงู‚ุฑูˆุง ุงู„ุชูˆุถูŠุญ ู„ู…ู† ุณุฃู„

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุฏูƒุชูˆุฑ ู‡ู†ุง ุดุฑุญ ุงุฏูุงู†ุณ ู…ุฌุงู†ูŠ ุจุงู„ูƒุงู…ู„ ( ุญุงู„ูŠุง ู…ูƒู…ู„ูŠู† ุฌุงุจุชุฑูŠู† ) ู„ุงู† ุงู„ุงุบู„ุจ ูŠุฑูŠุฏ ุดุฑุญ ู„ู‡ุงูŠ ุงู„ู…ุงุฏุฉ https://t.me/Explanation_phRam/1286